Morphic Holding — Company Overview, News & Financial Data
Morphic develops oral small-molecule integrin therapeutics to address chronic diseases, aiming for patient outcome improvement.
Morphic Holding
Company profile
About Morphic Holding
Morphic (NASDAQ:MORF) is focused on developing oral small-molecule integrin therapeutics. Integrins are a family of proteins that play a critical role in cell adhesion, which is a vital component of many biological processes including immune response and tissue repair. The company is leveraging its proprietary MInT Platform to discover and advance a pipeline of novel integrin therapeutics for serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases among others. Its projects aim to address unmet medical needs by creating efficacious and convenient oral medications, potentially replacing injectable treatments that dominate current therapies. With objectives centered on transforming integrin-targeted therapeutics, Morphic is dedicated to improving patient outcomes through innovative research and development practices.
Snapshot
2014Year founded
128Employees
Waltham, United StatesHead office
Loading Map...
Global footprint
Operations
All Locations
Waltham, US
Products and/or services of Morphic Holding
- MORF-057, an integrin inhibitor in development for treating inflammatory bowel disease with a focus on ulcerative colitis, showcasing potential for patient-friendly oral dosing.
- Integrin research platform, leveraging proprietary technology to discover and develop small molecule integrin therapeutics for a range of diseases, including fibrosis and cancer.
- Collaboration with AbbVie on developing oral integrin therapies, focusing on the avß6 integrin, highlights their commitment to advancing treatment options for fibrotic diseases.
- Partnership with Janssen for the discovery and development of integrin-targeted therapeutics, emphasizing the potential in treating conditions that currently have limited treatment options.
- Investment in precision medicine through developing a portfolio of oral small molecule integrin therapies, aimed at providing targeted, efficacious treatment options across a span of serious chronic diseases.
- Continuous engagement in scientific research and development to expand the understanding of integrin biology, thereby identifying novel therapeutic targets for unmet medical needs in various diseases.
Morphic Holding executive team
- Dr. Praveen P. Tipirneni M.B.A., M.D.CEO, MD & Director
- Dr. Bruce N. Rogers Ph.D.President
- Dr. Timothy A. Springer M.B.A., Ph.D.Founder, Independent Director & Member of Scientific Advisory Board
- Dr. Marc Schegerin M.B.A., M.D.CFO & COO
- Mr. Robert E. Farrell Jr., CPASenior VP of Finance & Chief Accounting Officer
- Dr. Blaise Lippa Ph.D.Chief Scientific Officer
- Mr. William D. DeVaul Esq.General Counsel & Secretary
- Mr. Aaron PeltaSenior Vice President of Business & Corporate Development
- Ms. Joanne GibbonsSenior Vice President of Regulatory Affairs
- Dr. Simon Cooper MBBSChief Medical Officer
GET YOUR GRAFA EDGE NOW
Sign up free to follow this company
We'll switch on a 30-day Edge trial as a welcome gift